Kite Pharma (KITE) Tops Q3 EPS by 51c

Kite Pharma (NASDAQ: KITE) reported Q3 EPS of ($1.10), $0.51 better than the analyst estimate of ($1.61). Revenue for the quarter came in at $7.34 million versus the consensus estimate of $4.94 million.

For earnings history and earnings-related data on Kite Pharma (KITE) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
• Kodiak Sciences Inc. (KOD) Misses Q2 EPS by 7c